Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Vanda Pharmaceuticals Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2003, the company has made significant strides in developing innovative therapies for patients with unmet medical needs, particularly in the fields of central nervous system disorders and sleep disorders.
Vanda's core products, including the FDA-approved medications Fanapt and Hetlioz, are distinguished by their unique mechanisms of action and targeted therapeutic approaches. The company has established a strong market position, recognised for its commitment to advancing treatment options and improving patient outcomes. With a focus on research and development, Vanda continues to explore new avenues for growth and innovation in the pharmaceutical landscape.
-19 vs industry average
Vanda Pharmaceuticals Inc.’s score of 23 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Vanda Pharmaceuticals Inc. yet.
Vanda Pharmaceuticals Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company.
As a result, Vanda Pharmaceuticals has not established any significant climate commitments or initiatives aimed at reducing its carbon footprint. The lack of emissions data and reduction strategies suggests that the company may still be in the early stages of developing a comprehensive climate action plan.
In the broader context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction, often setting Science-Based Targets (SBTi) to align with global climate goals. However, without specific commitments or data, Vanda Pharmaceuticals remains unaligned with these industry trends.
No climate goals have been disclosed for Vanda Pharmaceuticals Inc. yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more